Listed

enVVeno Medical Corp

NVNONasdaqCIK 1661053HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$4.5m, Q3 FY2026
Net income−$4.4m, Q3 FY2026
enVVeno Medical Corp, income statement, quarterly
Line itemUnitQ4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Q3 FY20262026-09-30
Revenue$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Cost of revenue$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Gross profit$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Research and development$k2,981Research and development, Q4 FY2023, three months to 2023-12-31$3.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K/A filed 2025-02-28, accession 0001493152-25-008739. Derived: 12-month figure less the 9-month figure.Report this figure3,052Research and development, Q1 FY2024, three months to 2024-03-31$3.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-04-30, accession 0001641172-25-007908.Report this figure2,825Research and development, Q2 FY2024, three months to 2024-06-30$2.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-07-31, accession 0001493152-25-011521.Report this figure2,859Research and development, Q3 FY2024, three months to 2024-09-30$2.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-10-30, accession 0001493152-25-020215.Report this figure3,513Research and development, Q4 FY2024, three months to 2024-12-31$3.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-26, accession 0001493152-26-012928. Derived: 12-month figure less the 9-month figure.Report this figure2,557Research and development, Q1 FY2025, three months to 2025-03-31$2.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-06, accession 0001493152-26-021490.Report this figure2,891Research and development, Q2 FY2025, three months to 2025-06-30$2.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-07-30, accession 0001493152-26-035452.Report this figure2,585Research and development, Q3 FY2025, three months to 2025-09-30$2.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-10-29, accession 0001493152-26-049269.Report this figure1,948Research and development, Q4 FY2025, three months to 2025-12-31$1.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-26, accession 0001493152-26-012928. Derived: 12-month figure less the 9-month figure.Report this figure2,111Research and development, Q1 FY2026, three months to 2026-03-31$2.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-06, accession 0001493152-26-021490.Report this figure2,076Research and development, Q2 FY2026, three months to 2026-06-30$2.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-07-30, accession 0001493152-26-035452.Report this figure2,876Research and development, Q3 FY2026, three months to 2026-09-30$2.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-10-29, accession 0001493152-26-049269.Report this figure
Selling, general and administrative$k3,297Selling, general and administrative, Q4 FY2023, three months to 2023-12-31$3.3m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K/A filed 2025-02-28, accession 0001493152-25-008739. Derived: 12-month figure less the 9-month figure.Report this figure2,451Selling, general and administrative, Q1 FY2024, three months to 2024-03-31$2.5m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-04-30, accession 0001641172-25-007908.Report this figure2,629Selling, general and administrative, Q2 FY2024, three months to 2024-06-30$2.6m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-07-31, accession 0001493152-25-011521.Report this figure3,311Selling, general and administrative, Q3 FY2024, three months to 2024-09-30$3.3m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-10-30, accession 0001493152-25-020215.Report this figure3,186Selling, general and administrative, Q4 FY2024, three months to 2024-12-31$3.2m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2026-03-26, accession 0001493152-26-012928. Derived: 12-month figure less the 9-month figure.Report this figure2,397Selling, general and administrative, Q1 FY2025, three months to 2025-03-31$2.4m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-05-06, accession 0001493152-26-021490.Report this figure4,158Selling, general and administrative, Q2 FY2025, three months to 2025-06-30$4.2m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-07-30, accession 0001493152-26-035452.Report this figure2,298Selling, general and administrative, Q3 FY2025, three months to 2025-09-30$2.3m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-10-29, accession 0001493152-26-049269.Report this figure2,065Selling, general and administrative, Q4 FY2025, three months to 2025-12-31$2.1m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2026-03-26, accession 0001493152-26-012928. Derived: 12-month figure less the 9-month figure.Report this figure1,951Selling, general and administrative, Q1 FY2026, three months to 2026-03-31$2.0m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-05-06, accession 0001493152-26-021490.Report this figure1,720Selling, general and administrative, Q2 FY2026, three months to 2026-06-30$1.7m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-07-30, accession 0001493152-26-035452.Report this figure1,658Selling, general and administrative, Q3 FY2026, three months to 2026-09-30$1.7m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-10-29, accession 0001493152-26-049269.Report this figure
Operating income$k(6,278)Operating income, Q4 FY2023, three months to 2023-12-31−$6.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K/A filed 2025-02-28, accession 0001493152-25-008739. Derived: 12-month figure less the 9-month figure.Report this figure(5,503)Operating income, Q1 FY2024, three months to 2024-03-31−$5.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-04-30, accession 0001641172-25-007908.Report this figure(5,454)Operating income, Q2 FY2024, three months to 2024-06-30−$5.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-07-31, accession 0001493152-25-011521.Report this figure(6,170)Operating income, Q3 FY2024, three months to 2024-09-30−$6.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-10-30, accession 0001493152-25-020215.Report this figure(6,699)Operating income, Q4 FY2024, three months to 2024-12-31−$6.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-26, accession 0001493152-26-012928. Derived: 12-month figure less the 9-month figure.Report this figure(4,954)Operating income, Q1 FY2025, three months to 2025-03-31−$5.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-06, accession 0001493152-26-021490.Report this figure(7,049)Operating income, Q2 FY2025, three months to 2025-06-30−$7.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-30, accession 0001493152-26-035452.Report this figure(4,883)Operating income, Q3 FY2025, three months to 2025-09-30−$4.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-10-29, accession 0001493152-26-049269.Report this figure(4,013)Operating income, Q4 FY2025, three months to 2025-12-31−$4.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-26, accession 0001493152-26-012928. Derived: 12-month figure less the 9-month figure.Report this figure(4,062)Operating income, Q1 FY2026, three months to 2026-03-31−$4.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-06, accession 0001493152-26-021490.Report this figure(3,796)Operating income, Q2 FY2026, three months to 2026-06-30−$3.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-30, accession 0001493152-26-035452.Report this figure(4,534)Operating income, Q3 FY2026, three months to 2026-09-30−$4.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-10-29, accession 0001493152-26-049269.Report this figure
Net income$k(5,649)Net income, Q4 FY2023, three months to 2023-12-31−$5.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K/A filed 2025-02-28, accession 0001493152-25-008739. Derived: 12-month figure less the 9-month figure.Report this figure(4,992)Net income, Q1 FY2024, three months to 2024-03-31−$5.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-04-30, accession 0001641172-25-007908.Report this figure(4,956)Net income, Q2 FY2024, three months to 2024-06-30−$5.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-07-31, accession 0001493152-25-011521.Report this figure(5,642)Net income, Q3 FY2024, three months to 2024-09-30−$5.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-30, accession 0001493152-25-020215.Report this figure(6,229)Net income, Q4 FY2024, three months to 2024-12-31−$6.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-26, accession 0001493152-26-012928. Derived: 12-month figure less the 9-month figure.Report this figure(4,503)Net income, Q1 FY2025, three months to 2025-03-31−$4.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-06, accession 0001493152-26-021490.Report this figure(6,694)Net income, Q2 FY2025, three months to 2025-06-30−$6.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-30, accession 0001493152-26-035452.Report this figure(4,539)Net income, Q3 FY2025, three months to 2025-09-30−$4.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-29, accession 0001493152-26-049269.Report this figure(3,736)Net income, Q4 FY2025, three months to 2025-12-31−$3.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-26, accession 0001493152-26-012928. Derived: 12-month figure less the 9-month figure.Report this figure(3,849)Net income, Q1 FY2026, three months to 2026-03-31−$3.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-06, accession 0001493152-26-021490.Report this figure(3,600)Net income, Q2 FY2026, three months to 2026-06-30−$3.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-30, accession 0001493152-26-035452.Report this figure(4,367)Net income, Q3 FY2026, three months to 2026-09-30−$4.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-29, accession 0001493152-26-049269.Report this figure
Diluted EPS$ per sharenot reported(0.31)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.31 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-04-30, accession 0001641172-25-007908.Report this figure(0.31)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.31 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-07-31, accession 0001493152-25-011521.Report this figure(0.35)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.35 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-10-30, accession 0001493152-25-020215.Report this figurenot reported(7.75)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$7.75 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-06, accession 0001493152-26-021490.Report this figure(11.52)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$11.52 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-30, accession 0001493152-26-035452.Report this figure(7.89)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$7.89 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-10-29, accession 0001493152-26-049269.Report this figurenot reported(5.89)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$5.89 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-06, accession 0001493152-26-021490.Report this figure(5.37)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$5.37 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-30, accession 0001493152-26-035452.Report this figure(6.29)Diluted EPS, Q3 FY2026, three months to 2026-09-30−$6.29 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-10-29, accession 0001493152-26-049269.Report this figure
Basic EPS$ per sharenot reported(0.31)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.31 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-04-30, accession 0001641172-25-007908.Report this figure(0.31)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.31 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-07-31, accession 0001493152-25-011521.Report this figure(0.35)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.35 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-10-30, accession 0001493152-25-020215.Report this figurenot reported(7.75)Basic EPS, Q1 FY2025, three months to 2025-03-31−$7.75 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-06, accession 0001493152-26-021490.Report this figure(11.52)Basic EPS, Q2 FY2025, three months to 2025-06-30−$11.52 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-07-30, accession 0001493152-26-035452.Report this figure(7.89)Basic EPS, Q3 FY2025, three months to 2025-09-30−$7.89 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-10-29, accession 0001493152-26-049269.Report this figurenot reported(5.89)Basic EPS, Q1 FY2026, three months to 2026-03-31−$5.89 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-06, accession 0001493152-26-021490.Report this figure(5.37)Basic EPS, Q2 FY2026, three months to 2026-06-30−$5.37 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-07-30, accession 0001493152-26-035452.Report this figure(6.29)Basic EPS, Q3 FY2026, three months to 2026-09-30−$6.29 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-10-29, accession 0001493152-26-049269.Report this figure

Balance sheet

Cash and equivalents$2.6m, Q3 FY2026
Shareholders' equity$16.9m, Q3 FY2026
enVVeno Medical Corp, balance sheet, quarterly
Line itemUnitFY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Q3 FY20262026-09-30
Cash and equivalents$m3.6Cash and equivalents, FY2023, at 2023-12-31$3.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K/A filed 2025-02-28, accession 0001493152-25-008739.Report this figure2.3Cash and equivalents, Q1 FY2024, at 2024-03-31$2.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-08, accession 0001493152-24-018225.Report this figure2.4Cash and equivalents, Q2 FY2024, at 2024-06-30$2.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-07-31, accession 0001493152-24-029737.Report this figure17.9Cash and equivalents, Q3 FY2024, at 2024-09-30$17.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-10-31, accession 0001493152-24-043100.Report this figure1.8Cash and equivalents, FY2024, at 2024-12-31$1.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-26, accession 0001493152-26-012928.Report this figure2.9Cash and equivalents, Q1 FY2025, at 2025-03-31$2.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-04-30, accession 0001641172-25-007908.Report this figure2.0Cash and equivalents, Q2 FY2025, at 2025-06-30$2.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-07-31, accession 0001493152-25-011521.Report this figure1.5Cash and equivalents, Q3 FY2025, at 2025-09-30$1.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-10-30, accession 0001493152-25-020215.Report this figure3.1Cash and equivalents, FY2025, at 2025-12-31$3.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-10-29, accession 0001493152-26-049269.Report this figure2.6Cash and equivalents, Q1 FY2026, at 2026-03-31$2.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-06, accession 0001493152-26-021490.Report this figure2.8Cash and equivalents, Q2 FY2026, at 2026-06-30$2.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-07-30, accession 0001493152-26-035452.Report this figure2.6Cash and equivalents, Q3 FY2026, at 2026-09-30$2.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-10-29, accession 0001493152-26-049269.Report this figure
Current assets$m46.9Current assets, FY2023, at 2023-12-31$46.9m. XBRL concept us-gaap:AssetsCurrent. 10-K/A filed 2025-02-28, accession 0001493152-25-008739.Report this figure43.2Current assets, Q1 FY2024, at 2024-03-31$43.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-08, accession 0001493152-24-018225.Report this figure39.5Current assets, Q2 FY2024, at 2024-06-30$39.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-07-31, accession 0001493152-24-029737.Report this figure49.1Current assets, Q3 FY2024, at 2024-09-30$49.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-10-31, accession 0001493152-24-043100.Report this figure43.7Current assets, FY2024, at 2024-12-31$43.7m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-26, accession 0001493152-26-012928.Report this figure39.5Current assets, Q1 FY2025, at 2025-03-31$39.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-04-30, accession 0001641172-25-007908.Report this figure35.6Current assets, Q2 FY2025, at 2025-06-30$35.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-07-31, accession 0001493152-25-011521.Report this figure31.5Current assets, Q3 FY2025, at 2025-09-30$31.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-10-30, accession 0001493152-25-020215.Report this figure28.8Current assets, FY2025, at 2025-12-31$28.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-10-29, accession 0001493152-26-049269.Report this figure25.5Current assets, Q1 FY2026, at 2026-03-31$25.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-06, accession 0001493152-26-021490.Report this figure22.1Current assets, Q2 FY2026, at 2026-06-30$22.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-07-30, accession 0001493152-26-035452.Report this figure19.0Current assets, Q3 FY2026, at 2026-09-30$19.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-10-29, accession 0001493152-26-049269.Report this figure
Total assets$m48.6Total assets, FY2023, at 2023-12-31$48.6m. XBRL concept us-gaap:Assets. 10-K/A filed 2025-02-28, accession 0001493152-25-008739.Report this figure44.8Total assets, Q1 FY2024, at 2024-03-31$44.8m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-08, accession 0001493152-24-018225.Report this figure41.0Total assets, Q2 FY2024, at 2024-06-30$41.0m. XBRL concept us-gaap:Assets. 10-Q filed 2024-07-31, accession 0001493152-24-029737.Report this figure50.4Total assets, Q3 FY2024, at 2024-09-30$50.4m. XBRL concept us-gaap:Assets. 10-Q filed 2024-10-31, accession 0001493152-24-043100.Report this figure45.0Total assets, FY2024, at 2024-12-31$45.0m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-26, accession 0001493152-26-012928.Report this figure40.6Total assets, Q1 FY2025, at 2025-03-31$40.6m. XBRL concept us-gaap:Assets. 10-Q filed 2025-04-30, accession 0001641172-25-007908.Report this figure36.6Total assets, Q2 FY2025, at 2025-06-30$36.6m. XBRL concept us-gaap:Assets. 10-Q filed 2025-07-31, accession 0001493152-25-011521.Report this figure32.4Total assets, Q3 FY2025, at 2025-09-30$32.4m. XBRL concept us-gaap:Assets. 10-Q filed 2025-10-30, accession 0001493152-25-020215.Report this figure29.6Total assets, FY2025, at 2025-12-31$29.6m. XBRL concept us-gaap:Assets. 10-Q filed 2026-10-29, accession 0001493152-26-049269.Report this figure26.1Total assets, Q1 FY2026, at 2026-03-31$26.1m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-06, accession 0001493152-26-021490.Report this figure22.7Total assets, Q2 FY2026, at 2026-06-30$22.7m. XBRL concept us-gaap:Assets. 10-Q filed 2026-07-30, accession 0001493152-26-035452.Report this figure19.5Total assets, Q3 FY2026, at 2026-09-30$19.5m. XBRL concept us-gaap:Assets. 10-Q filed 2026-10-29, accession 0001493152-26-049269.Report this figure
Current liabilities$m1.4Current liabilities, FY2023, at 2023-12-31$1.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K/A filed 2025-02-28, accession 0001493152-25-008739.Report this figure1.5Current liabilities, Q1 FY2024, at 2024-03-31$1.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-08, accession 0001493152-24-018225.Report this figure1.7Current liabilities, Q2 FY2024, at 2024-06-30$1.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-07-31, accession 0001493152-24-029737.Report this figure2.2Current liabilities, Q3 FY2024, at 2024-09-30$2.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-10-31, accession 0001493152-24-043100.Report this figure2.1Current liabilities, FY2024, at 2024-12-31$2.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-26, accession 0001493152-26-012928.Report this figure1.7Current liabilities, Q1 FY2025, at 2025-03-31$1.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-04-30, accession 0001641172-25-007908.Report this figure3.0Current liabilities, Q2 FY2025, at 2025-06-30$3.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-07-31, accession 0001493152-25-011521.Report this figure2.4Current liabilities, Q3 FY2025, at 2025-09-30$2.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-10-30, accession 0001493152-25-020215.Report this figure2.1Current liabilities, FY2025, at 2025-12-31$2.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-10-29, accession 0001493152-26-049269.Report this figure2.1Current liabilities, Q1 FY2026, at 2026-03-31$2.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-06, accession 0001493152-26-021490.Report this figure1.9Current liabilities, Q2 FY2026, at 2026-06-30$1.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-07-30, accession 0001493152-26-035452.Report this figure2.6Current liabilities, Q3 FY2026, at 2026-09-30$2.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-10-29, accession 0001493152-26-049269.Report this figure
Total liabilities$m2.4Total liabilities, FY2023, at 2023-12-31$2.4m. XBRL concept us-gaap:Liabilities. 10-K/A filed 2025-02-28, accession 0001493152-25-008739.Report this figure2.5Total liabilities, Q1 FY2024, at 2024-03-31$2.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-08, accession 0001493152-24-018225.Report this figure2.6Total liabilities, Q2 FY2024, at 2024-06-30$2.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-07-31, accession 0001493152-24-029737.Report this figure3.0Total liabilities, Q3 FY2024, at 2024-09-30$3.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-10-31, accession 0001493152-24-043100.Report this figure2.8Total liabilities, FY2024, at 2024-12-31$2.8m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-26, accession 0001493152-26-012928.Report this figure2.3Total liabilities, Q1 FY2025, at 2025-03-31$2.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-04-30, accession 0001641172-25-007908.Report this figure3.5Total liabilities, Q2 FY2025, at 2025-06-30$3.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-07-31, accession 0001493152-25-011521.Report this figure2.9Total liabilities, Q3 FY2025, at 2025-09-30$2.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-10-30, accession 0001493152-25-020215.Report this figure2.4Total liabilities, FY2025, at 2025-12-31$2.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-10-29, accession 0001493152-26-049269.Report this figure2.4Total liabilities, Q1 FY2026, at 2026-03-31$2.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-06, accession 0001493152-26-021490.Report this figure2.0Total liabilities, Q2 FY2026, at 2026-06-30$2.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-07-30, accession 0001493152-26-035452.Report this figure2.6Total liabilities, Q3 FY2026, at 2026-09-30$2.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-10-29, accession 0001493152-26-049269.Report this figure
Shareholders' equity$m46.2Shareholders' equity, FY2023, at 2023-12-31$46.2m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-26, accession 0001493152-26-012928.Report this figure42.4Shareholders' equity, Q1 FY2024, at 2024-03-31$42.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-07-31, accession 0001493152-25-011521.Report this figure38.4Shareholders' equity, Q2 FY2024, at 2024-06-30$38.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-10-30, accession 0001493152-25-020215.Report this figure47.4Shareholders' equity, Q3 FY2024, at 2024-09-30$47.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-10-30, accession 0001493152-25-020215.Report this figure42.2Shareholders' equity, FY2024, at 2024-12-31$42.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-29, accession 0001493152-26-049269.Report this figure38.3Shareholders' equity, Q1 FY2025, at 2025-03-31$38.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-07-30, accession 0001493152-26-035452.Report this figure33.1Shareholders' equity, Q2 FY2025, at 2025-06-30$33.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-29, accession 0001493152-26-049269.Report this figure29.4Shareholders' equity, Q3 FY2025, at 2025-09-30$29.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-29, accession 0001493152-26-049269.Report this figure27.1Shareholders' equity, FY2025, at 2025-12-31$27.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-29, accession 0001493152-26-049269.Report this figure23.7Shareholders' equity, Q1 FY2026, at 2026-03-31$23.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-07-30, accession 0001493152-26-035452.Report this figure20.7Shareholders' equity, Q2 FY2026, at 2026-06-30$20.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-29, accession 0001493152-26-049269.Report this figure16.9Shareholders' equity, Q3 FY2026, at 2026-09-30$16.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-29, accession 0001493152-26-049269.Report this figure

Cash flow

Operating cash flow−$3.2m, Q3 FY2026
Capital expenditure$0, Q4 FY2025
enVVeno Medical Corp, cash flow, quarterly
Line itemUnitQ4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Q3 FY20262026-09-30
Operating cash flow$k(4,973)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$5.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K/A filed 2025-02-28, accession 0001493152-25-008739. Derived: 12-month figure less the 9-month figure.Report this figure(3,550)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$3.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-04-30, accession 0001641172-25-007908.Report this figure(3,907)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$3.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-07-31, accession 0001493152-25-011521. Derived: 6-month figure less the 3-month figure.Report this figure(4,276)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$4.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-10-30, accession 0001493152-25-020215. Derived: 9-month figure less the 6-month figure.Report this figure(5,105)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$5.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-26, accession 0001493152-26-012928. Derived: 12-month figure less the 9-month figure.Report this figure(4,018)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$4.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-06, accession 0001493152-26-021490.Report this figure(3,715)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$3.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-30, accession 0001493152-26-035452. Derived: 6-month figure less the 3-month figure.Report this figure(4,392)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$4.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-10-29, accession 0001493152-26-049269. Derived: 9-month figure less the 6-month figure.Report this figure(3,443)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$3.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-26, accession 0001493152-26-012928. Derived: 12-month figure less the 9-month figure.Report this figure(3,238)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$3.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-06, accession 0001493152-26-021490.Report this figure(3,549)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$3.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-30, accession 0001493152-26-035452. Derived: 6-month figure less the 3-month figure.Report this figure(3,178)Operating cash flow, Q3 FY2026, three months to 2026-09-30−$3.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-10-29, accession 0001493152-26-049269. Derived: 9-month figure less the 6-month figure.Report this figure
Capital expenditure$k4.0Capital expenditure, Q4 FY2023, three months to 2023-12-31$4.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K/A filed 2025-02-28, accession 0001493152-25-008739. Derived: 12-month figure less the 9-month figure.Report this figure10.0Capital expenditure, Q1 FY2024, three months to 2024-03-31$10.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-04-30, accession 0001641172-25-007908.Report this figure14.0Capital expenditure, Q2 FY2024, three months to 2024-06-30$14.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-07-31, accession 0001493152-25-011521. Derived: 6-month figure less the 3-month figure.Report this figure9.0Capital expenditure, Q3 FY2024, three months to 2024-09-30$9.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-10-30, accession 0001493152-25-020215. Derived: 9-month figure less the 6-month figure.Report this figure4.0Capital expenditure, Q4 FY2024, three months to 2024-12-31$4.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-26, accession 0001493152-26-012928. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported0.0Capital expenditure, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-10-29, accession 0001493152-26-049269. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-26, accession 0001493152-26-012928. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reported

Shares

Diluted shares (weighted)694,000, Q3 FY2026
enVVeno Medical Corp, shares, quarterly
Line itemUnitQ1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30Q3 FY20262026-09-30
Diluted shares (weighted)m shares11.2Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3111,231,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-08, accession 0001493152-24-018225.Report this figure11.2Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3011,231,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-07-31, accession 0001493152-24-029737.Report this figure11.2Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3011,231,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-10-31, accession 0001493152-24-043100.Report this figure16.1Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3116,057,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-04-30, accession 0001641172-25-007908.Report this figure16.1Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3016,067,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-07-31, accession 0001493152-25-011521.Report this figure16.1Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3016,067,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-10-30, accession 0001493152-25-020215.Report this figure0.6Diluted shares (weighted), Q1 FY2025, three months to 2025-03-31581,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-06, accession 0001493152-26-021490.Report this figure0.6Diluted shares (weighted), Q2 FY2025, three months to 2025-06-30581,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-07-30, accession 0001493152-26-035452.Report this figure0.6Diluted shares (weighted), Q3 FY2025, three months to 2025-09-30575,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-10-29, accession 0001493152-26-049269.Report this figure0.7Diluted shares (weighted), Q1 FY2026, three months to 2026-03-31654,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-06, accession 0001493152-26-021490.Report this figure0.7Diluted shares (weighted), Q2 FY2026, three months to 2026-06-30671,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-07-30, accession 0001493152-26-035452.Report this figure0.7Diluted shares (weighted), Q3 FY2026, three months to 2026-09-30694,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-10-29, accession 0001493152-26-049269.Report this figure

Shares outstanding: 694,826Shares outstanding, period not labelled, at 2026-10-27694,826 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-10-29, accession 0001493152-26-049269.Report this figure at Oct 27, 2026, from the cover of the 10-Q filed Oct 29, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 19:27 ET. Listed shows no prices and gives no investment advice.